Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 3
2014 6
2015 2
2016 4
2017 4
2018 6
2019 3
2020 1
2021 5
2022 8
2023 8
2024 10
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
BNCT pancreatic cancer treatment strategy with glucose-conjugated boron drug.
Fujimoto T, Teraishi F, Kanehira N, Tajima T, Sakurai Y, Kondo N, Yamagami M, Kuwada A, Morihara A, Kitamatsu M, Fujimura A, Suzuki M, Takaguchi Y, Shigeyasu K, Fujiwara T, Michiue H. Fujimoto T, et al. Among authors: shigeyasu k. Biomaterials. 2024 Sep;309:122605. doi: 10.1016/j.biomaterials.2024.122605. Epub 2024 May 9. Biomaterials. 2024. PMID: 38754291
Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B-NIT).
Fujimoto T, Yamasaki O, Kanehira N, Matsushita H, Sakurai Y, Kenmotsu N, Mizuta R, Kondo N, Takata T, Kitamatsu M, Igawa K, Fujimura A, Otani Y, Shirakawa M, Shigeyasu K, Teraishi F, Togashi Y, Suzuki M, Fujiwara T, Michiue H. Fujimoto T, et al. Among authors: shigeyasu k. Cancer Sci. 2024 Oct;115(10):3231-3247. doi: 10.1111/cas.16298. Epub 2024 Aug 9. Cancer Sci. 2024. PMID: 39119813 Free PMC article.
ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer.
Umeda H, Shigeyasu K, Takahashi T, Moriwake K, Kondo Y, Yoshida K, Takeda S, Yano S, Matsumi Y, Kishimoto H, Fuji T, Yasui K, Yamamoto H, Takagi K, Kayano M, Michiue H, Nakamura K, Mori Y, Teraishi F, Tazawa H, Umeda Y, Kagawa S, Goel A, Fujiwara T. Umeda H, et al. Among authors: shigeyasu k. Mol Cancer. 2025 Apr 16;24(1):116. doi: 10.1186/s12943-025-02312-y. Mol Cancer. 2025. PMID: 40241135 Free PMC article.
Tumor-targeted fluorescence labeling systems for cancer diagnosis and treatment.
Tazawa H, Shigeyasu K, Noma K, Kagawa S, Sakurai F, Mizuguchi H, Kobayashi H, Imamura T, Fujiwara T. Tazawa H, et al. Among authors: shigeyasu k. Cancer Sci. 2022 Jun;113(6):1919-1929. doi: 10.1111/cas.15369. Epub 2022 Apr 18. Cancer Sci. 2022. PMID: 35398956 Free PMC article. Review.
Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients.
Takahashi T, Shigeyasu K, Kondo Y, Takeda S, Umeda H, Moriwake K, Kayano M, Sakurai Y, Nakamura S, Takahashi M, Nitta K, Yoshida K, Matsumi Y, Michiue H, Yamamoto H, Kishimoto H, Teraishi F, Shoji R, Kanaya N, Kashima H, Kakiuchi Y, Kuroda S, Kagawa S, Fujiwara T. Takahashi T, et al. Among authors: shigeyasu k. BMC Cancer. 2025 Jan 2;25(1):1. doi: 10.1186/s12885-024-13370-8. BMC Cancer. 2025. PMID: 39748254 Free PMC article.
58 results